Cetuximab as salvage monotherapy in chemotherapy‑refractory metastatic colorectal cancer: A single‑center report

Mekata,Eiji; Endo,Yoshihiro; Sonoda,Hiromichi; Shimizu,Tomoharu; Kawai,Yuki; Umeda,Tomoko; Shiomi,Hisanori; Naka,Shigeyuki; Kubota,Yoshihiro; Murata,Satoshi; Yamamoto,Hiroshi; Abe,Hajime; Tani,Tohru

doi:10.3892/ol.2013.1477

October 2013 Volume 6 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October 2013 Volume 6 Issue 4

Full Size Image

Article

Cetuximab as salvage monotherapy in chemotherapy‑refractory metastatic colorectal cancer: A single‑center report

Authors:
- Eiji Mekata
- Yoshihiro Endo
- Hiromichi Sonoda
- Tomoharu Shimizu
- Yuki Kawai
- Tomoko Umeda
- Hisanori Shiomi
- Shigeyuki Naka
- Yoshihiro Kubota
- Satoshi Murata
- Hiroshi Yamamoto
- Hajime Abe
- Tohru Tani
View Affiliations / Copyright

Affiliations: Department of Surgery, Shiga University of Medical Science, Otsu, Shiga 520‑2192, Japan, Department of Clinical Nursing, Shiga University of Medical Science, Otsu, Shiga 520‑2192, Japan
Pages: 1011-1014
|
Published online on: July 19, 2013

https://doi.org/10.3892/ol.2013.1477
Expand metrics +

Abstract

In July 2008, cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), was approved in Japan for clinical use against chemotherapy‑refractory metastatic colorectal cancer (mCRC). At Shiga University of Medical Science, between December 2007 and April 2012, a total of 24 EGFR‑positive mCRC cases were administered immunohistochemistry with cetuximab as salvage monotherapy. The safety, side‑effects and clinical efficacy of the treatment, including response rate, time to treatment failure, progression‑free and overall survival, K‑ras mutation status and impact on outcome, were investigated. The patient tumor growth control rate (TCR) was 38%, the mean time to progression (TTP) was 9.8 weeks [95% confidence interval (CI), 7.2‑12.4] and the mean overall survival (OS) was 49.4 weeks (95% CI, 30.1‑68.8). The most common adverse reactions reported were skin reactions, including acne (67%), hand‑foot syndrome (16.7%) and paronychia (16.7%), followed by hypocalcemia (50%), hypomagnesemia (16%), stomatitis (20%) and gastrointestinal disorders (12%). The results of the present single‑center study demonstrated that cetuximab monotherapy is beneficial for the treatment of chemotherapy‑refractory patients with mCRC and that it has an acceptable level of safety and manageable side‑effects.

View Figures

View References

1	Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Tokyo Japan. Foundation for promotion of cancer research. Cancer statistics in Japan-2009. http://ganjoho.jp/data/public/statistics/backnumber/2011/files/cancer_statistics_2011.pdf. Accessed April 27, 2012
3	Jonker DJ, O’Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med. 357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
4	Au HJ, Karapetis CS, O’Callaghan CJ, et al: Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO. 17 Trial. J Clin Oncol. 27:1822–1828. 2009. View Article : Google Scholar : PubMed/NCBI
5	Mizota A, Shitara K, Kondo C, et al: Retrospective analysis of cetuximab monotherapy for patients with irinotecan-intolerant metastatic colorectal cancer. Int J Clin Oncol. 16:416–420. 2011. View Article : Google Scholar : PubMed/NCBI
6	Engstrom PF, Arnoletti JP, Benson AB III, et al; National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer. J Natl Compr Canc Netw. 7:778–831. 2009.PubMed/NCBI
7	De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 304:1812–1820. 2010.PubMed/NCBI
8	Kimura H, Sakai K, Arao T, et al: Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 98:1275–1280. 2007. View Article : Google Scholar
9	Bibeau F, Lopez-Crapez E, Di Fiore F, et al: Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol. 27:1122–1129. 2009.
10	Lièvre A, Bachet JB, Boige V, et al: KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 26:374–379. 2008.
11	Piessevaux H, Buyse M, De Roock W, et al: Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Ann Oncol. 20:1375–1382. 2009. View Article : Google Scholar
12	Sobrero AF, Maurel J, Fehrenbacher L, et al: EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 26:2311–2319. 2008. View Article : Google Scholar : PubMed/NCBI
13	Vincenzi B, Santini D, Rabitti C, et al: Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer. 94:792–797. 2006. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Cetuximab as salvage monotherapy in chemotherapy‑refractory metastatic colorectal cancer: A single‑center report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles